MENS
Jyong Biotech Ltd. Ordinary SharesMENS
MENS
About: Jyong Biotech Ltd is a science-driven biotechnology company based in Taiwan and is committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia (primarily Taiwan and mainland China). It has been dedicated to the research and development of new drugs with high safety and efficacy. It has been developing a series of drug candidates, including one core drug candidate at NDA stage, one clinical-stage key drug candidate and other preclinical-stage drug candidates.
–
Funds holding %
of 7,331 funds
–
Analysts bullish %
Fund manager confidence
Research analyst outlook
We haven’t received any recent analyst ratings for MENS.
Financial journalist opinion
Neutral
Seeking Alpha
1 week ago
Jyong Biotech's Plant‑Based Pipeline Targets Huge Markets But Risks Remain
Jyong Biotech develops botanical drugs for urinary disorders. Their lead asset is clearly MCS‑2, which is currently restarting Phase 3 trials after a previous FDA setback. Their pipeline targets large unmet BPH, prostate cancer prevention, and IC markets. However, their botanical approach could be a potential “first‑in‑class” as a safer alternative. MENS recent IPO raised roughly $20 million and gave them a healthy cash runway. Though note that additional trials could accelerate cash burn.

Neutral
GlobeNewsWire
2 weeks ago
Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention
New Taipei City, Taiwan, July 22, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, announced completion of its Nasdaq IPO ceremony, and that it participated at the world's largest biotechnology exhibition BIO 2025 International Convention, where it engaged with other global pharmaceutical companies.

Positive
Seeking Alpha
1 month ago
U.S. IPO Weekly Recap: Sizable Precision Medicine And Insurance IPOs Raise A Combined $902 Million
A handful of IPOs and blank checks priced in the short holiday week, led by two sizable issuers. Two smaller IPOs also priced this past week. One IPO is currently scheduled to list in the week ahead, although some small names may also join the calendar throughout the week.

Neutral
GlobeNewsWire
1 month ago
Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering
New Taipei City, Taiwan, June 18, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced the closing of its initial public offering (the “Offering”) of 2,666,667 ordinary shares (the “Ordinary Shares”) at a public offering price of $7.5 per share for aggregate gross proceeds of approximately $20 million, before deducting underwriting discounts and other offering expenses. The Ordinary Shares commenced trading on Nasdaq Global Market on June 17, 2025, under the ticker symbol “MENS”. The Offering closed on June 18, 2025.

Charts implemented using Lightweight Charts™